Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
- DOI
- 10.1002/cncr.70396
- Published
- 2026 May 1
- Container
- Cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cncr.70396,
title = {Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.},
author = {Kim TM and Williamson SK and Papadopoulos KP and Hamid O and Dy GK and McDermott R and Birnbaum A and Kaczmar JM and Lakhani N and Rischin D and Sarker D and Dowlati A and Zhu XH and Malhotra J and Pouliot JF and Mani J and Brennan L and Fang F and Chen S and Salvati M and Lowy I and Khaled A and Lewis KD and Kroog G and Fury MG and Cho BC},
year = {2026},
journal = {Cancer},
doi = {10.1002/cncr.70396},
url = {https://doi.org/10.1002/cncr.70396}
}RIS
TY - JOUR TI - Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies. AU - Kim TM AU - Williamson SK AU - Papadopoulos KP AU - Hamid O AU - Dy GK AU - McDermott R AU - Birnbaum A AU - Kaczmar JM AU - Lakhani N AU - Rischin D AU - Sarker D AU - Dowlati A AU - Zhu XH AU - Malhotra J AU - Pouliot JF AU - Mani J AU - Brennan L AU - Fang F AU - Chen S AU - Salvati M AU - Lowy I AU - Khaled A AU - Lewis KD AU - Kroog G AU - Fury MG AU - Cho BC PY - 2026 JO - Cancer DO - 10.1002/cncr.70396 UR - https://doi.org/10.1002/cncr.70396 ER -
APA
TM, K., SK, W., KP, P., O, H., GK, D., R, M., A, B., JM, K., N, L., D, R., D, S., A, D., XH, Z., J, M., JF, P., J, M., L, B., F, F., S, C., M, S., I, L., A, K., KD, L., G, K., MG, F., & BC, C. (2026). Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.. Cancer. https://doi.org/10.1002/cncr.70396
Source records
- pubmed · retrieved 2026-09-26T09:08:34.954Z